BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 36583742)

  • 1. Bacterial metabolite butyrate in modulating sorafenib-targeted microRNAs to curtail its resistance in hepatocellular carcinoma.
    Kumar M; Kaur R; Kanthaje S; Dhiman RK; Chakraborti A
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):5823-5839. PubMed ID: 36583742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miR-23b-3p Modulating Cytoprotective Autophagy and Glutamine Addiction in Sorafenib Resistant HepG2, a Hepatocellular Carcinoma Cell Line.
    Kaur R; Kanthaje S; Taneja S; Dhiman RK; Chakraborti A
    Genes (Basel); 2022 Aug; 13(8):. PubMed ID: 36011286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MiR-375 attenuates sorafenib resistance of hepatocellular carcinoma cells by inhibiting cell autophagy.
    Wang D; Yang J
    Acta Biochim Pol; 2023 Apr; 70(2):239-246. PubMed ID: 37068178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells.
    Li W; Dong X; He C; Tan G; Li Z; Zhai B; Feng J; Jiang X; Liu C; Jiang H; Sun X
    J Exp Clin Cancer Res; 2019 May; 38(1):183. PubMed ID: 31053148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exosomal MiR-744 Inhibits Proliferation and Sorafenib Chemoresistance in Hepatocellular Carcinoma by Targeting PAX2.
    Wang G; Zhao W; Wang H; Qiu G; Jiang Z; Wei G; Li X
    Med Sci Monit; 2019 Sep; 25():7209-7217. PubMed ID: 31553714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma.
    Pollutri D; Patrizi C; Marinelli S; Giovannini C; Trombetta E; Giannone FA; Baldassarre M; Quarta S; Vandewynckel YP; Vandierendonck A; Van Vlierberghe H; Porretti L; Negrini M; Bolondi L; Gramantieri L; Fornari F
    Cell Death Dis; 2018 Jan; 9(1):4. PubMed ID: 29305580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
    Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SNGH16 regulates cell autophagy to promote Sorafenib Resistance through suppressing miR-23b-3p via sponging EGR1 in hepatocellular carcinoma.
    Jing Z; Ye X; Ma X; Hu X; Yang W; Shi J; Chen G; Gong L
    Cancer Med; 2020 Jun; 9(12):4324-4338. PubMed ID: 32324343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LncRNA FOXD2-AS1 as a competitive endogenous RNA against miR-150-5p reverses resistance to sorafenib in hepatocellular carcinoma.
    Sui C; Dong Z; Yang C; Zhang M; Dai B; Geng L; Lu J; Yang J; Xu M
    J Cell Mol Med; 2019 Sep; 23(9):6024-6033. PubMed ID: 31210410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maternal embryonic leucine zipper kinase serves as a potential prognostic marker and leads to sorafenib chemoresistance modified by miR-142-5p in hepatocellular carcinoma.
    Li H; Gai L; Wu Z; Li F
    Mol Biol Rep; 2022 Apr; 49(4):3015-3024. PubMed ID: 35013864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-25 enhances autophagy and promotes sorafenib resistance of hepatocellular carcinoma via targeting FBXW7.
    Feng X; Zou B; Nan T; Zheng X; Zheng L; Lan J; Chen W; Yu J
    Int J Med Sci; 2022; 19(2):257-266. PubMed ID: 35165511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
    Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C
    Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The lncRNA lnc-TSI antagonizes sorafenib resistance in hepatocellular carcinoma via downregulating miR-4726-5p expression and upregulating KCNMA1 expression.
    Chen F; Jiang J; Liu D; Li H; Dong L; Song Y; Zhang Y; Wang J; Qin Y; Zhao G
    J Mol Histol; 2024 Feb; 55(1):83-96. PubMed ID: 38165571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The miR-30a-5p/CLCF1 axis regulates sorafenib resistance and aerobic glycolysis in hepatocellular carcinoma.
    Zhang Z; Tan X; Luo J; Yao H; Si Z; Tong JS
    Cell Death Dis; 2020 Oct; 11(10):902. PubMed ID: 33097691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-138-1-3p sensitizes sorafenib to hepatocellular carcinoma by targeting PAK5 mediated β-catenin/ABCB1 signaling pathway.
    Li TT; Mou J; Pan YJ; Huo FC; Du WQ; Liang J; Wang Y; Zhang LS; Pei DS
    J Biomed Sci; 2021 Aug; 28(1):56. PubMed ID: 34340705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription.
    Lin Z; Xia S; Liang Y; Ji L; Pan Y; Jiang S; Wan Z; Tao L; Chen J; Lin C; Liang X; Xu J; Cai X
    Theranostics; 2020; 10(19):8834-8850. PubMed ID: 32754282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of miR-193a and sorafenib on hepatocellular carcinoma cells.
    Salvi A; Conde I; Abeni E; Arici B; Grossi I; Specchia C; Portolani N; Barlati S; De Petro G
    Mol Cancer; 2013 Dec; 12():162. PubMed ID: 24330766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LncRNA LIMT (LINC01089) contributes to sorafenib chemoresistance via regulation of miR-665 and epithelial to mesenchymal transition in hepatocellular carcinoma cells.
    Sun J; Zheng X; Wang B; Cai Y; Zheng L; Hu L; Lu X; Xie S; Zhang X; Liu H; Ye L
    Acta Biochim Biophys Sin (Shanghai); 2022 Jan; 54(2):261-270. PubMed ID: 35130616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-541 potentiates the response of human hepatocellular carcinoma to sorafenib treatment by inhibiting autophagy.
    Xu WP; Liu JP; Feng JF; Zhu CP; Yang Y; Zhou WP; Ding J; Huang CK; Cui YL; Ding CH; Zhang X; Lu B; Xie WF
    Gut; 2020 Jul; 69(7):1309-1321. PubMed ID: 31727683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vimentin as a potential therapeutic target in sorafenib resistant HepG2, a HCC model cell line.
    Makol A; Kaur H; Sharma S; Kanthaje S; Kaur R; Chakraborti A
    Clin Mol Hepatol; 2020 Jan; 26(1):45-53. PubMed ID: 31564085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.